Serum Diamine Oxidase Values, Indicating Histamine Intolerance, Influence Lactose Tolerance
Download the paper clicking here
Abstract: Lactose intolerance (LIT) is one of the major causes of irritable bowel syndrome (IBS) spectrum complaints. Differences in inadequate lactose digestion are described as various LIT phenotypes with basically unknown pathophysiology. In LIT patients, we retrospectively assessed the effect of histamine intolerance (HIT) on expiratory hydrogen (H2) during H2 lactose breath tests. In a retrospective evaluation of charts from 402 LIT patients, 200 patients were identified as having only LIT. The other 202 LIT patients were found to additionally have diamine oxidase (DAO) values of <10 U/mL, which indicates histamine intolerance (HIT). To identify HIT, standardized questionnaires, low serum DAO values and responses to a histamine-reduced diet were used. Patients were separated into three diagnostic groups according to the result of H2 breath tests: (1) LIT, with an H2 increase of >20 parts per million (ppm), but a blood glucose (BG) increase of >20 mg/dL, (2) LIT with an H2 increase of 20 ppm in combination with a BG increase of <20 mg/dL, and (3) LIT with an exhaled H2 increase of <20 ppm and BG increase of <20 mg/dL. Pairwise comparison with the KruskalWallis test was used to compare the areas under the curve (AUC) of LIT and LIT with HIT patients. Exhaled H2 values were significantly higher in H2 > 20 ppm and BG < 20 mg/dL patients with LIT and HIT (p = 0.007). This diagnostic group also showed a significant higher number of patients (p = 0.012) and a significant higher number of patients with gastrointestinal (GI) symptoms during H2 breath tests (p < 0.001). Therefore, low serum DAO values, indicating HIT, influence results of lactose tolerance breath tests.
Citation: Schnedl,W.J.; Meier-Allard, N.; Michaelis, S.; Lackner, S.; Enko, D.; Mangge, H.; Holasek, S.J. Serum Diamine Oxidase Values, Indicating Histamine Intolerance, Influence Lactose Tolerance Breath Test Results. Nutrients 2022, 14, 2026. https://doi.org/10.3390/nu14102026
Wolfgang J. Schnedl 1,* , Nathalie Meier-Allard 2, Simon Michaelis 3 , Sonja Lackner 2 , Dietmar Enko 3,4 , Harald Mangge 4 and Sandra J. Holasek 2
1 Practice for General Internal Medicine, Dr. Theodor Körnerstrasse 19b, 8600 Bruck an der Mur, Austria
2 Division of Immunology and Pathophysiology, Otto Loewi Research Center, Medical University of Graz, Heinrichstrasse 31a, 8010 Graz, Austria; nathalie.allard@medunigraz.at (N.M.-A.); sonja.lackner@medunigraz.at (S.L.); sandra.holasek@medunigraz.at (S.J.H.)
3 Institute of Clinical Chemistry, Laboratory Medicine, Hospital Hochsteiermark, Vordernberger Straße 42, 8700 Leoben, Austria; simon.michaelis@kages.at (S.M.); enko.dietmar@gmx.at (D.E.)
4 Clinical Institute of Medical, Chemical Laboratory Diagnosis, Medical University of Graz, Auenbruggerplatz 30, 8036 Graz, Austria; harald.mangge@klinikum-graz.at
- Correspondence: w.schnedl@dr-schnedl.at; Tel.: +43-3612-55833; Fax: +43-3612-55833-22
Intestinal Dysbiosis in Patients with Histamine Intolerance
New study published about microbiota, histamine intolerance and DAO deficiency by the research team of the University of Barcelona (Dr. Mª Carmen Vidal). Adding clinical and scientific evidence every day.
Download the scientific paper through here
Abstract: An underlying cause of histamine intolerance is diamine oxidase (DAO) deficiency, which leads to defective homeostasis and a higher systemic absorption of histamine. Impaired DAO activity may have a genetic, pharmacological or pathological origin. A recent proposal also suggests it can arise from an alteration in the gut microbiota, although only one study has explored this hypothesis to date. A greater abundance of histamine-secreting bacteria in the gut could lead to the development of histamine ntolerance. Thus, the aim of this study was to characterize the composition of the intestinal microbiota of patients with histamine intolerance symptoms and compare it with that of healthy individuals. The study was performed by sequencing bacterial 16S rRNA genes (V3-V4 region) and analyzing the data using the EzBioCloud Database. Dysbiosis of the gut microbiota was observed in the histamine intolerance group who, in comparison with the healthy individuals, had a significantly lower proportion of Prevotellaceae, Ruminococcus, Faecalibacterium and Faecablibacterium prausnitzii, which are bacteria related to gut health. They also had a significantly higher abundance of histaminesecreting bacteria, including the genera Staphylococcus and Proteus, several unidentified genera belonging to the family Enterobacteriaceae and the species Clostridium perfringens and Enterococcus faecalis. A greater abundance of histaminogenic bacteria would favor the accumulation of high levels of histamine in the gut, its subsequent absorption in plasma and the appearance of adverse effects, even in individuals without DAO deficiency.
Sònia Sánchez-Pérez 1,2,3 , Oriol Comas-Basté 1,2,3 , Adriana Duelo 1,2,3, M. Teresa Veciana-Nogués 1,2,3 ,
Mercedes Berlanga 4 , M. Luz Latorre-Moratalla 1,2,3,† and M. Carmen Vidal-Carou 1,2,3,*,†
1 Department de Nutrició, Ciències de l’Alimentació i Gastronomía, Facultat de Farmàcia i Ciències de l’Alimentació, Campus de l’Alimentació de Torribera, Universitat de Barcelona (UB), Av. Prat de la Riba 171, 08921 Santa Coloma de Gramenet, Spain; soniasanchezperez@ub.edu (S.S.-P.); oriolcomas@ub.edu (O.C.-B.); aduelo@ub.edu (A.D.); veciana@ub.edu (M.T.V.-N.); mariluzlatorre@ub.edu (M.L.L.-M.)
2 Institut de Recerca en Nutrició i Seguretat Alimentària (INSAUB), Universitat de Barcelona (UB), Av. Prat de la Riba 171, 08921 Santa Coloma de Gramenet, Spain
3 Xarxa d’Innovació Alimentària (XIA), C/Baldiri Reixac 4, 08028 Barcelona, Spain
4 Departament de Biologia, Sanitat i Mediambient, Secció de Microbiologia, Facultat de Farmàcia i Ciències de l’Alimentació, Universitat de Barcelona (UB), Av. Joan XXIII 27-31, 08028 Barcelona, Spain; mberlanga@ub.edu
- Correspondence: mcvidal@ub.edu
† These authors contributed equally to this work.
Citation: Sánchez-Pérez, S.; Comas-Basté, O.; Duelo, A.; Veciana-Nogués, M.T.; Berlanga, M.; Latorre-Moratalla, M.L.; Vidal-Carou, M.C. Intestinal Dysbiosis in Patients with Histamine Intolerance. Nutrients 2022, 14, 1774. https://doi.org/10.3390/nu14091774
Histamine Intolerance—A Kind of Pseudoallergic Reaction
Biomolecules 2022, 12, 454. https://doi.org/10.3390/biom12030454
Ying Zhao 1,2,† , Xiaoyan Zhang 1,2,† , Hengxi Jin 2 , Lu Chen 1,2, Jiang Ji 1,2,* and Zhongwei Zhang 3,*
1 Department of Dermatology, The Second Affiliated Hospital of Soochow University, Suzhou 215000, China;
nanjjzhaoying@126.com (Y.Z.); hiohikari@163.com (X.Z.); chenlu1275@163.com (L.C.)
2 Department of Dermatology and Venereology, Suzhou Medical College of Soochow University,
Suzhou 215000, China; jinhengxi1995@163.com
3 Department of Biochemistry and Molecular Biology, School of Medicine, Nantong University,
Nantong 226001, China
*Correspondence: jijiang@suda.edu.cn (J.J.); zhangzwei22@gmail.com (Z.Z.); Tel.: +86-0512-6778-3484 (J.J.)
† These authors contributed equally to this work.
Download th review here
Abstract:
Histamine intolerance (HIT) is a common disorder associated with impaired histamine metabolism. Notwithstanding, it is often misdiagnosed as other diseases because of its lack of specific clinical manifestations. HIT did not gain traction until the early 21st century. In this review, we will focus on the latest research and elaborate on the clinical manifestations of HIT, including its manifestations in special populations such as atopic dermatitis (AD) and chronic urticaria (CU), as well as the latest understanding of its etiology and pathogenesis. In addition, we will explore the latest treatment strategies for HIT and the treatment of specific cases.
Medical nutrition industry prepares for the first International Congress on DAO Deficiency – NutraSalud
Article published in NutraSalud magazine on November 2, 2021. Publication link
International experts on the various disorders caused by DAO deficiency, in fields as diverse as the digestive system, neurology, genetics, psychiatry, allergology and nutrition, will participate in the first International Congress on DAO Deficiency, organized by DR Healthcare.
DR Healthcare, a business unit of AB Biotek, part of the multinational Associated British Foods, presents the final program for the first International Congress on DAO Deficiency, which takes place on Thursday, November 4.
The conference, which will be broadcast virtually from 10:00 am to 6:45 pm, will feature medical and scientific experts to discuss the most important advances in the treatment of diamine oxidase deficiency (DAO), a disorder that affects people with migraines, fibromyalgia, intestinal problems, skin problems, attention deficit hyperactivity disorder (ADHD), among other pathologies.
DAO is an intestinal enzyme naturally secreted by the human body, although it can also be consumed as a nutritional supplement to treat its deficiency, which often leads to histamine disorders, a problem faced by millions of people worldwide.
The inaugural session will be given by Dr. Mª Carmen Vidal-Carou, Professor of Nutrition and Bromatology and Director of the Food and Nutrition Campus of the University of Barcelona, who will speak about histamine intolerance.
Experts in fields as diverse as the digestive system, neurology, genetics, psychiatry, allergology and nutrition, all of them related to DAO deficiency and its disorders, will participate in the conference, such as Dr. Oriol Comas-Basté, Dr. Walburga Dieterich, Dr. Eva Ruiz Casares, Dr. Hilario Blasco-Fontecilla, and Dr. Joan Izquierdo, among others.
“We are immersed in finding new ways to offer a better quality of life to all those with DAO deficiency,” said Juanjo Duelo, founder of DR Healthcare. “The future is promising, and bringing together leading medical experts and pioneering scientists in this unique meeting to share and exchange information and data will help us to join collective efforts to advance for the benefit of patients.”
“We want to promote awareness of DAO deficiency with an extensive program that includes presentations of scientific studies from specialists worldwide,” mentions Carlos de Lecea, physician and global portfolio manager of AB Biotek’s Human Nutrition and Health division. “The collaborative and multidisciplinary approach to the diagnosis and treatment of DAO deficiency will contribute to a paradigm shift in this field, whose relevance is growing every day due to the increase in the number of patients.
The event, supported by the International DAO Deficiency Society, will also feature a 3D virtual exhibition section and the opportunity for interaction between registered guests, participants and speakers.
AB Mauri set to lead first-ever virtual congress into DAO enzyme deficiency
Article published in bakeryandsnacks.com the 29-oct-2021, by Gill Hyslop. Publication link
The business unit of AB Biotek – which is part of the global yeast and bakery ingredients specialist – is hosting the first International Congress of DAO Deficiency online on 4 November.
International Congress of DAO Deficiency 2021
You are invited to map a new future in managing DAO Deficiency attending the International Congress on DAO Deficiency.
SAVE THE DATE: November 4th 2021
At DR HEALTHCARE, we are pioneers in DAO Deficiency. Since our beginnings, scientific evidence and research have driven each one of our steps. The time has come to share this knowledge with the scientific and medical community, nutrition specialists, and patients who suffer from this metabolic deficiency’s different recurring symptoms.
Together, we can go farther.
Which is why we are delighted to invite you to the International Congress of DAO Deficiency, to be held 4 November 2021, in virtual format.
Our end goal:
is to reinforce knowledge of DAO Deficiency through a complete programme of scientific sessions, with experts of worldwide renown. With a forward-looking approach, we will address both diagnosis and treatment, as well as how knowledge of DAO Deficiency has led to a paradigm shift in the field of medical nutrition.
The event will be held entirely online:
as required by this exceptional situation caused by the pandemic. However, this way we will also be able to make our shared knowledge and experiences available to professionals all around the world, saving on costs and travel, and reducing our ecological footprint.
Technology will make it possible:
for guests to attend all conferences through an immersive, comprehensive experience. In addition to the extensive medical and scientific programme, the exhibition with 3D stands, and online interaction with guests, congress participants and speakers will provide a one-of-a-kind stage with services just like at a face-to-face event. All in real time.
We eagerly await you.
Warm regards,
Gerald Dard Juanjo Duelo
Managing Director ABBiotek Global Business Development Director Enzymes
AB Biotek Acquires Spanish Biomedical DR Healthcare
Respective leaders in fermentation science and DAO-based medical nutrition join together to focus on innovative enzyme-based solutions for the human nutrition & health market.
PETERBOROUGH, U.K. 26 may 2021 – AB Biotek, a global business division of Associated British Foods plc – today announces that it has acquired DR Healthcare, a biomedical company focused on the dietary management of chronic diseases based in Barcelona, Spain.
This acquisition enables AB Biotek to boost its growing portfolio of differentiated microbiome modulating solutions for human nutrition and health. The acquisition adds diamine oxidase (DAO), an important intestinal enzyme, that will expand AB Biotek’s already strong commercial portfolio of probiotic yeast strains.
DAO, naturally secreted by the human body, is widely known as a critical enzyme at the core of reducing symptoms of many of today’s ailments, including migraine, food intolerances and attention deficit hyperactivity disorder, prevalent in millions of people around the world.
Juanjo Duelo, the founder of DR Healthcare, will remain with the business.
“With the acquisition of DR Healthcare, we now have the next stepping stone in shaping our science-based organization to serve the fast-growing human nutrition and health space,” said Gerald Dard, global managing director, AB Biotek. “DR Healthcare has a strong track record in this area, and we welcome our new colleagues who are equally passionate about the health and wellness of today’s consumers.”
“I am very excited about this new chapter as our companies have many shared values, from advanced health solutions and deep science to an extreme passion for what we do,” said Juanjo Duelo. “The future is bright under the good ownership of AB Biotek, and the timing is perfect to bring new, innovative technologies to improve the wellbeing of those people who suffer from various pathologies associated with the deficiency of DAO.”
About AB Biotek
AB Biotek contributes to the success of customers through the delivery of customized fermentation-based, sustainable solutions containing proprietary and/or purposefully sourced microorganisms to created differentiated food, beverage, health & nutrition business opportunities. Science and advanced microorganism fermentation technology are core enablers. AB Biotek has commercial scale production and research development facilities located around the world. For more information about our product applications and unmatched technical service capabilities, please visit www.abbiotek.com.
About DR Healthcare
Founded in Barcelona, Spain, in 2007, DR Healthcare is a biomedical company specialized in medical nutrition and dedicated to the research, development, innovation, marketing and licensing of new nutraceuticals, functional foods, active ingredients and customized solutions. Our medical nutrition products are aimed at dietary management of chronic diseases, physiological dysfunctions and/or metabolic diseases, mainly associated with metabolic disorders caused by a deficiency of the intestinal enzyme diamine oxidase (DAO). DR Healthcare produces DAO for both human and animal use and offers proprietary solutions for the food, pharmaceutical, veterinary and animal health industries. More information is available at www.dr-healthcare.com/en.
Patrick Barry +1.314.540.3865
LLYC
Tina Díaz adiaz@llorenteycuenca.com
Míriam Cusí mcusi@llorenteycuenca.com
Cristina Vilà cvila@llorenteycuenca.com
Histamine Intolerance Originates in the Gut
Nutrients 2021, 13, 1262. https://doi.org/10.3390/nu13041262
Wolfgang J. Schnedl 1,* and Dietmar Enko 2
1 General Internal Medicine Practice, Dr. Theodor Körnerstrasse 19b, A-8600 Bruck, Austria
2 Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz,
Auenbruggerplatz 15, A-8036 Graz, Austria; enko.dietmar@gmx.at
- Correspondence: w.schnedl@dr-schnedl.at; Tel.: +43-3612-55833; Fax: +43-3612-55833-22
Download the paper here
Abstract:
Histamine intolerance (HIT) is assumed to be due to a deficiency of the gastrointestinal (GI) enzyme diamine oxidase (DAO) and, therefore, the food component histamine not being degraded and/or absorbed properly within the GI tract. Involvement of the GI mucosa in various disorders and diseases, several with unknown origin, and the effects of some medications seem to reduce gastrointestinal DAO activity. HIT causes variable, functional, nonspecific, non-allergic GI and extra-intestinal complaints. Usually, evaluation for HIT is not included in differential diagnoses of patients with unexplained, functional GI complaints or in the here-listed disorders and diseases. The clinical diagnosis of HIT is challenging, and the thorough anamnesis of all HIT-linked complaints, using a standardized questionnaire, is the mainstay of HIT diagnosis. So far, DAO values in serum have not been established to correlate with DAO activity in the gut, but the diagnosis of HIT may be supported with determination of a low serum DAO value. A targeted dietary intervention, consisting of a histamine-reduced diet and/or supplementation with oral DAO capsules, is helpful to reduce HIT-related symptoms. This manuscript will present why histamine should also be taken into account in the differential diagnoses of patients with various diseases and disorders of unknown origin, but with association to functional gastrointestinal complaints. In this review, we discuss currently increasing evidence that HIT is primarily a gastrointestinal disorder and that it originates in the gut.
Association of Diamine oxidase (DAO) variants with the risk for migraine from North Indian population
Association of Diamine oxidase (DAO) variants with the risk for migraine from North Indian population
Sukhvinder Kaura,⁎, Arif Alib, Yaser Siahbalaeic, Uzair Ahmadc, Fazila Nargisc, A.K. Pandeyd,
Balkirat Singhe
a UGC-PDF, Gene Expression Lab, Department of Biosciences, Jamia Millia Islamia, New Delhi, India
b UGC-BSR-FF, Department of Biosciences, Jamia Millia Islamia, New Delhi, India
c Department of Biosciences, Jamia Millia Islamia, New Delhi, India
d Head, Department of Physiology, ESIC Medical College & Hospital, Faridabad, India
e NC Medical College & Hospital, Panipat, India
A B S T R A C T
Background: Migraine is a common neurovascular disorder affected by various levels of neurotransmitters. Low histamine metabolism is also related with pathophysiology of migraine. As diamine oxidase (DAO) gene variants are linked with higher levels of histamine in migraine patients, we investigated the possible relationship of two variants rs2052129 and rs10156191of this gene with migraine risk in North Indian population.
Methods: A case-control study for 250 migraine patients and 250 matched healthy controls was conducted by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
Results: We found statistically significant differences in allelic frequencies of rs2052129 (p = .009, OR = 1.462; 95% CI: 1.098–1.947) and rs10156191 (p = .019, OR = 1.430; 95% CI: 1.060–1.928) variants in DAO gene. For rs1015691, we were able to show statistically significant association at all genotypic, dominant and allelic levels in both MA (for T allele, p = .020; OR = 1.662, 95% CI: 1.083–2.551) as well as in female subgroup (for T allele, p = .025, OR = 1.460; 95% CI: 1.049–2.033). But no such significant association was found in clinical sub grouping of migraine in rs2052129 as p > .05. However in gender analysis, protective effect of T allele in male migraine patients for rs2052129 (OR < 1) was found.
Conclusions: Our findings clearly indicated that female patient with rs10156191T allele and in MA subgroup showed an increased risk for migraine. Our data also indicated that rs2052129T variant showed a significant role in migraine susceptibility of this population.
According to a study the 90% of migraines can be treated with the enzyme DAO – Interview of RTVE to Juanjo Duelo, CEO of DR Healthcare
7/3/2013 – interview to Juanjo Duelo in rtve 24h. Language: Spanish
These last hours has been spoken about migraines, from which has been made public that the fifteen percent of the world’s population suffers from these tremendous headaches that go beyond a headache. Juanjo Duelo, in addition to suffering from migraines, directs a research team that assures to be able to determine the causes of migraines and most importantly, their solution.